Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) [Phase 3]

View source ↗

Summary

Phase 3 CARES trial update for CAEL-101 in Mayo Stage IIIa AL amyloidosis. The study is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• CAEL-101 (birtamimab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: AL Amyloidosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING